Skip to content
Search

Latest Stories

#VotePharmacy Manifesto: Pharmacy bodies urge political parties to adopt 6-point plan

#VotePharmacy Manifesto: Pharmacy bodies urge political parties to adopt 6-point plan
Pharmacy leaders advocate for comprehensive reforms to secure the future of community pharmacies amid funding and operational challenges

The Chief Executives of Community Pharmacy England(CPE), the Company Chemists’ Association(CCA), the National Pharmacy Association(NPA), and the Chair of the Royal Pharmaceutical Society’s(RPS) English Pharmacy Board (EPB) have issued an open letter to political parties, urging the adoption of the six-point plan outlined in the #VotePharmacy general election manifesto.

This initiative aims to bolster community pharmacy in the run-up to the next general election.


Launched in March 2024, the #VotePharmacy manifesto serves as a comprehensive guide for the community pharmacy sector.

It aims to help local pharmacy committees (LPCs) and pharmacy owners engage with political parties and candidates.

The open letter highlights the critical role of the 10,500+ community pharmacies in England.

These pharmacies have been pivotal in providing accessible healthcare and medicines to patients.

The recent introduction of the Pharmacy First service underscores the expanding role of pharmacies.

With over 98 per cent of pharmacies participating in this service, more than a million people have already benefited, illustrating the sector's capacity to alleviate pressures on the NHS.

However, the letter points out that the community pharmacy sector is facing a crisis.

Government funding has not kept pace with the increasing demands of the NHS and rising operational costs.

The Health and Social Care Committee has recognised the potential of pharmacies to enhance healthcare access but also noted that the current Community Pharmacy Contractual Framework(CPCF) is outdated and requires a complete overhaul.

The six-point plan detailed in the manifesto includes:

1. Filling the funding gap and committing to a sustainable, long-term funding solution.

2. Supporting and enhancing the community pharmacy workforce.

3. Conducting a thorough review of the medicines supply chain.

4. Rolling out an enhanced Pharmacy First service across England.

5. Empowering community pharmacists with a roadmap for independent prescribing.

6. Making pharmacies central to public health, prevention, and reducing health inequalities.

The pharmacy bodies emphasise that with proper investment, the sector can significantly enhance patient access, alleviate GP workloads, and support the NHS in reducing care backlogs.

They call on all political parties to adopt this six-point plan to ensure a robust future for community pharmacy.

More For You

RPS backs Pharmacist Support "Gift in Wills" initiative

The ‘Gift in Wills’ initiative is delivered in partnership with Bequeathed.

Photo credit: gettyimages

Leave a legacy: RPS partners with Pharmacist Support to promote ‘Gift in Wills’

The Royal Pharmaceutical Society (RPS) has announced its support for the ‘Gift in Wills’ initiative run by Pharmacist Support, coinciding with the charity’s birthday celebrations today (Tuesday 15 April).

This collaboration allows RPS members to create a free will while also helping to safeguard the future of vital support services for the pharmacy profession.

Keep ReadingShow less
Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less